Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.

Eur J Haematol · 2025 · PMC11613577 · PMID 39252514

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

In addition, a clear trend towards an improved overall response rate (78% vs. 51%) was demonstrated in the FLAVIDA group.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.